Neuroendocrine Tumors Pipeline 2024 | Amgen, Eli Lilly and Company, GlaxoSmithKline, Hutchison Medipharma Limited, Ipsen, Seneca Therapeutics, Crinetics Pharmaceuticals, ADC Therapeutics, BeiGene

DelveInsight's, "Neuroendocrine Tumors Pipeline Insight 2024" report provides comprehensive insights about 115+ companies and 130+ pipeline drugs in Neuroendocrine Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neuroendocrine Tumors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Neuroendocrine Tumors Pipeline. Dive into DelveInsight's comprehensive report today! @ Neuroendocrine Tumors Pipeline Outlook [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Neuroendocrine Tumors Pipeline Report

* July 2024:- Georgiamune Inc - A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination With Anti-PD-1 in Advanced Solid Tumors. GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).
* July 2024:- UNICANCER - Dostarlimab as First-line Treatment for Patients With dMMR/MSI (Non-colorectal/Non-endometrial) Locally Advanced or Metastatic Cancer: a Randomized Phase 2 Trial (Cohort Pan-MSI ACSE) With Crossover in the Standard Arm at Progression.
* July 2024:- Merck Sharp & Dohme LLC- A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051). Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Researchers want to learn if different doses of pembrolizumab can cause at least 1 of the types of cancer to get smaller or go away.
* DelveInsight's Neuroendocrine Tumors Pipeline analysis depicts a robust space with 115+ active players working to develop 130+ pipeline treatment therapies.
* The leading Neuroendocrine Tumors Companies such as Amgen, Eli Lilly and Company, GlaxoSmithKline, Hutchison Medipharma Limited, Ipsen, Seneca Therapeutics, Crinetics Pharmaceuticals, ADC Therapeutics, BeiGene, Camurus, EpicentRx, RayzeBio, Inc., Shenzhen Chipscreen Biosciences Co., Ltd., Vyriad, Inc. and others.
* Promising Neuroendocrine Tumors Therapies such as Ipilimumab, Nivolumab, Pembrolizumab, Niraparib, Apalutamide, Selpercatinib, Cabozantinib, Vandetanib , and others.

Stay ahead with the most recent pipeline outlook for Neuroendocrine Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Neuroendocrine Tumors Approved Drugs [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Neuroendocrine Tumors Emerging Drugs

* RYZ101: RayzeBio, Inc.

RYZ101 is an investigational, targeted RPT designed to deliver a highly potent alpha-emitting radioisotope, Actinium-225 (Ac225), to solid tumors expressing SSTR2. RYZ101 leverages DOTATATE, a known binder and linker used in other radiopharmaceutical produts. RYZ101 uses Ac225 instead of the Lu177 used in Lutathera and thus delivers hundreds of times more potency in cancer cell killing. The higher potency of RYZ101 can provide significant clinical benefit to patients. RYZ101 utilizes a proprietary and patent protected formulation. The drug is being developed for gastroenteropancreatic neuroendocrine tumor, pancreatic net, neuroendocrine tumors, extensive stage small cell lung cancer (ES-SCLC), and other tumors.

* SVV-001: Seneca Therapeutics

SVV-001, an oncolytic virus of the genus Seneca in the Picornaviridae family. SVV-001 is characterized by its ability to replicate selectively in certain human tumor cells ("SVV-permissive cells"), namely those that express TEM8, the receptor of SVV. SVV-001 is non-pathogenic in humans and animals. SVV-001 and the Seneca genus was originally discovered in 2001 at Novartis Pharmaceuticals by Dr. Paul Hallenbeck. SVV-001 was further developed as a novel cancer therapeutic at Neotropix, Inc. SVV-001 has been extensively tested in over 30 non-clinical cancer models, including immunotherapeutic settings, and in three clinical trials for various solid cancer namely neuroendocrine tumors such as carcinoids, small cell lung cancer and a variety of pediatric cancers. These trials confirmed the safety of intravenous dosing of SVV-001 and safety along with suggestions of significant clinical benefit. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

* Voyager-V1: Vyriad, Inc.

VSV-IFN-NIS (Voyager V1; VV1) is derived from VSV, a bullet-shaped, negative-sense RNA virus with low human seroprevalence; it is engineered to replicate selectively in and kill human cancer cells. VV1 encodes hIFN to increase antitumoral immune response and tumor specificity, plus the thyroidal sodium iodide symporter NIS to allow imaging of virus. VV1 is synergistic with different anti-PD-(L)1 antibodies in several tumor models. Currently the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

* ADCT-701: ADC Therapeutics

ADCT-701 is an ADC composed of a humanized IgG1 antibody against human DLK-1, site-specifically conjugated using Glycoconnect technology to PL1601, which contains a valine-alanine cleavable linker and the PBD dimer cytotoxin SG3199. In vitro, ADCT-701 demonstrated potent cytotoxicity in a panel of human cancer cell lines of different origin and levels of DLK-1, while its potency was strongly reduced in DLK-1-negative cell lines. In vivo, ADCT-701 showed potent anti-tumor activity in the DLK1-expressing neuroblastoma-derived SK-N-FI xenograft in which a single dose of ADCT-701 at 0.5 or 1 mg/kg showed dose-dependent anti-tumor activity compared to the vehicle- and isotype control ADC-treated mice. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

Explore groundbreaking therapies and clinical trials in the Neuroendocrine Tumors Pipeline. Access DelveInsight's detailed report now! @ Neuroendocrine Tumors Treatment Drugs [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Neuroendocrine Tumors Companies

Amgen, Eli Lilly and Company, GlaxoSmithKline, Hutchison Medipharma Limited, Ipsen, Seneca Therapeutics, Crinetics Pharmaceuticals, ADC Therapeutics, BeiGene, Camurus, EpicentRx, RayzeBio, Inc., Shenzhen Chipscreen Biosciences Co., Ltd., Vyriad, Inc. and others.

Neuroendocrine Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

Neuroendocrine Tumors Products have been categorized under various Molecule types such as

* Monoclonal antibody
* Small molecule
* Peptide

Unveil the future of Neuroendocrine Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Neuroendocrine Tumors Market Drivers and Barriers [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Neuroendocrine Tumors Pipeline Report

* Coverage- Global
* Neuroendocrine Tumors Companies- Amgen, Eli Lilly and Company, GlaxoSmithKline, Hutchison Medipharma Limited, Ipsen, Seneca Therapeutics, Crinetics Pharmaceuticals, ADC Therapeutics, BeiGene, Camurus, EpicentRx, RayzeBio, Inc., Shenzhen Chipscreen Biosciences Co., Ltd., Vyriad, Inc. and others.
* Neuroendocrine Tumors Therapies- Ipilimumab, Nivolumab, Pembrolizumab, Niraparib, Apalutamide, Selpercatinib, Cabozantinib, Vandetanib, and others.
* Neuroendocrine Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Neuroendocrine Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Neuroendocrine Tumors Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Neuroendocrine Tumors Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Neuroendocrine Tumors: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Neuroendocrine Tumors- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* RYZ101: RayzeBio, Inc.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* SVV-001: Seneca Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ADCT-701: ADC Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Product Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Neuroendocrine Tumors Key Companies
* Neuroendocrine Tumors Key Products
* Neuroendocrine Tumors- Unmet Needs
* Neuroendocrine Tumors- Market Drivers and Barriers
* Neuroendocrine Tumors- Future Perspectives and Conclusion
* Neuroendocrine Tumors Analyst Views
* Neuroendocrine Tumors Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=neuroendocrine-tumors-pipeline-2024-amgen-eli-lilly-and-company-glaxosmithkline-hutchison-medipharma-limited-ipsen-seneca-therapeutics-crinetics-pharmaceuticals-adc-therapeutics-beigene]
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/



This release was published on openPR.